drugset / Trial / NCT00002314

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

NCT00002314

Phase 2 Completed Hoffmann-La Roche
Open-labelTreatment

Summary

To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ro 24-7429 Small molecule Oral